Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després J-P, Fullerton HJ. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2015;CIR. 0000000000000350.

Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97:13–25.

Article  Google Scholar 

Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17:269–85.

Article  PubMed  Google Scholar 

Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol. 2014;109:444.

Article  PubMed  Google Scholar 

Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen W-H, Shou Z, Liu P. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492–8.

Article  CAS  PubMed  Google Scholar 

Maury C, Teppo AM. Circulating tumour necrosis factor-α (cachectin) in myocardial infarction. J Intern Med. 1989;225:333–6.

Article  CAS  PubMed  Google Scholar 

Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119:91–112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kleinbongard P, Schulz R, Heusch G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev. 2011;16:49–69.

Article  CAS  PubMed  Google Scholar 

Sun M, Dawood F, Wen W-H, Chen M, Dixon I, Kirshenbaum LA, Liu PP. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221–8.

Article  CAS  PubMed  Google Scholar 

Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H, Sekikawa K, Seishima M. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-α. J Am Coll Cardiol. 2002;39:1229–35.

Article  CAS  PubMed  Google Scholar 

Berry MF, Woo YJ, Pirolli TJ, Bish LT, Moise MA, Burdick JW, Morine KJ, Jayasankar V, Gardner TJ, Sweeney HL. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Heart Lung Transplant. 2004;23:1061–8.

Article  PubMed  Google Scholar 

Nakamura H, Umemoto S, Naik G, Moe G, Takata S, Liu P, Matsuzaki M. Induction of left ventricular remodeling and dysfunction in the recipient heart after donor heart myocardial infarction: new insights into the pathologic role of tumor necrosis factor-alpha from a novel heterotopic transplant–coronary ligation rat model. J Am Coll Cardiol. 2003;42:173–81.

Article  CAS  PubMed  Google Scholar 

Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD. The τumor necrosis factor-α converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry. 2002;41:9462–9.

Article  CAS  PubMed  Google Scholar 

Horiuchi T, Mitoma H, Harashima S-i, Tsukamoto H, Shimoda T. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335:225–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335:229–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Issuree PDA, Maretzky T, McIlwain DR, Monette S, Qing X, Lang PA, Swendeman SL, Park-Min K-H, Binder N, Kalliolias GD. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Investig. 2013;123:928–32.

CAS  PubMed  PubMed Central  Google Scholar 

Hannemann C, Schecker JH, Brettschneider A, Grune J, Rösener N, Weller A, Stangl V, Fisher EA, Stangl K, Ludwig A, Hewing B. Deficiency of inactive rhomboid protein 2 (iRhom2) attenuates diet-induced hyperlipidemia and early atherogenesis. Cardiovasc Res. 2022;118:156–68.

Article  CAS  PubMed  Google Scholar 

Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC). Eur Heart J. 2016;37:267–315.

Article  CAS  PubMed  Google Scholar 

Ibánez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio AL, Crea F, Goudevenos JA, Halvorsen S. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (English Ed). 2017;70:1082.

Google Scholar 

Szulik M, Pappas CJ, Jurcut R, Magro M, Peeters E, Goetschalckx K, Rademakers F, Desmet W, Voigt J-U. Clinical validation of a novel speckle-tracking–based ejection fraction assessment method. J Am Soc Echocardiogr. 2011;24:1092–100.

Article  PubMed  Google Scholar 

Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu Y-J, MacPherson G, Randolph GJ. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;blood-2010-02-258558.

Hewing B, Au SC-D, Ludwig A, Ellerbroek R, van Dijck P, Hartmann L, Grubitzsch H, Giannini C, Laule M, Stangl V. Severe aortic valve stenosis in adults is associated with increased levels of circulating intermediate monocytes. J Cardiovasc Transl Res. 2017;10:27–34.

Article  PubMed  Google Scholar 

Members ATF, Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.

Article  Google Scholar 

Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–6.

Article  CAS  PubMed  Google Scholar 

Başaran Y, Başaran MM, Babacan K, Ener B, Okay T, Gök H, Özdemir M. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology. 1993;44:332–7.

Article  PubMed  Google Scholar 

Hirschl M, Gwechenberger M, Binder T, Binder M, Graf S, Stefenelli T, Rauscha F, Laggner A, Sochor H. Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. Eur Heart J. 1996;17:1852–9.

Article  CAS  PubMed  Google Scholar 

Belge K-U, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+ CD16+ DR++ monocytes are a major source of TNF. J Immunol. 2002;168:3536–42.

Article  CAS  PubMed  Google Scholar 

Monden Y, Kubota T, Inoue T, Tsutsumi T, Kawano S, Ide T, Tsutsui H, Sunagawa K. Tumor necrosis factor-α is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am J Physiol-Heart Circ Physiol. 2007;293:H743–53.

Article  CAS  PubMed  Google Scholar 

Schulz R, Heusch G. Tumor necrosis factor-α and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation. 2009;119:1355–7.

Article  PubMed  Google Scholar 

Weskamp G, Tüshaus J, Li D, Feederle R, Maretzky T, Swendemann S, Falck-Pedersen E, McIlwain DR, Mak TW, Salmon JE. ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1). J Biol Chem. 2020;295:4350–8.